Croma-Pharma announces 9-Country Licensing Agreement with Crescita Therapeutics for Pliaglis

Croma-Pharma today announced that it has entered into an exclusive commercialization development license agreement with Crescita Therapeutics (TSX: CTX and OTC US: CRRTF), a growth-oriented, innovation-driven Canadian commercial dermatology company, for the rights to Pliaglis^® in nine countries including Germany, the United Kingdom, Ireland, Switzerland, Brazil, Romania, Belgium, the Netherlands and Luxembourg (“Territories”).